Cogent Biosciences, Inc. Annual Operating Income (Loss) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cogent Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2023.
  • Cogent Biosciences, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$75.4M, a 26.6% decline year-over-year.
  • Cogent Biosciences, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$260M, a 34.5% decline year-over-year.
  • Cogent Biosciences, Inc. annual Operating Income (Loss) for 2023 was -$208M, a 40.8% decline from 2022.
  • Cogent Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$148M, a 95.7% decline from 2021.
  • Cogent Biosciences, Inc. annual Operating Income (Loss) for 2021 was -$75.6M, a 8.09% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$208M -$60.3M -40.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-26
2022 -$148M -$72.3M -95.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-26
2021 -$75.6M +$6.65M +8.09% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-26
2020 -$82.2M -$50M -155% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 -$32.2M +$3.83M +10.6% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
2018 -$36M -$9.85M -37.7% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-26
2017 -$26.2M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.